Factors associated with potentially inappropriate phosphodiesterase-5 inhibitor use for pulmonary hypertension in the US, 2006–2015

BACKGROUND: Use of phosphodiesterase-5 inhibitors for Groups 2 and 3 pulmonary hypertension is rising nationally, despite guidelines recommending against this low-value practice. Although receiving care across healthcare systems is encouraged to increase Veterans’ access to specialists critical for...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Circ Cardiovasc Qual Outcomes
Glavni autori: Gillmeyer, Kari R., Rinne, Seppo T., Glickman, Mark E., Lee, Kyung Min, Shao, Qing, Qian, Shirley X., Klings, Elizabeth S., Maron, Bradley A., Hanlon, Joseph T., Miller, Donald R., Wiener, Renda Soylemez
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7344878/
https://ncbi.nlm.nih.gov/pubmed/32393128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCOUTCOMES.119.005993
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items